|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | INCB14943 | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|||
| 化学式 | C9H7ClFN5O2 |
||||||
| 分子量 | 271.64 | CAS No. | 914471-09-3 | ||||
| Solubility (25°C)* | 体外 | DMSO (warmed with 50ºC water bath) | 54 mg/mL (198.79 mM) | ||||
| Ethanol (warmed with 50ºC water bath) | 54 mg/mL (198.79 mM) | ||||||
| Water | Insoluble | ||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||
| 製品説明 | Epacadostat (INCB024360) analogue (INCB14943) は、IC50 が 67 nM の強力な競合的 IDO1 (インドールアミン-(2,3)-ジオキシゲナーゼ) 阻害剤です。現在フェーズ2。 |
|---|---|
| in vitro | In HeLa cells, INCB024360 shows higher inhibitory activity on IDO1 with IC50 of 19 nM. In coculture systems of human allogeneic lymphocytes with dendritic cells or tumor cells, INCB024360, via IDO1 inhibition, reverses T-cell suppression mediated by IDO-expressing HeLa cells or DCs, and increases the proliferation and functional activity of CD4+ T cells, CD8+ T cells, and NK cells. |
| in vivo | In mice bearing GM-CSF-secreting B16 tumors, INCB024360 (75 mg/kg b.i.d) causes dose dependent inhibition of tumor growth. INCB024360 significantly suppresses tumor growth in immunocompetent, but not immunodeficient, mice. |
| キナーゼアッセイ | IDO enzyme assays | |
|---|---|---|
| Human IDO with an N-terminal His tag is expressed in E.coli and purified to homogeneity. IDO catalyzes the oxidative cleavage of the pyrrole ring of the indole nucleus of tryptophan to yield N’-formylkynurenine. The assays are performed at room temperature using 20 nM IDO and 2 mM D-Trp in the presence of 20 mM ascorbate, 3.5 μM methylene blue and 0.2 mg/mL catalase in 50 mM potassium phosphate buffer (pH 6.5). The initial reaction rates are recorded by continuously following the absorbance increase at 321 nm due to the formation of N’-formlylkynurenine. | ||
| 動物実験 | 動物モデル | Mice bearing GM-CSF-secreting B16 tumors |
| 投薬量 | 75 mg/kg b.i.d | |
| 投与方法 | s.c. | |
|
| IDO1 inhibitors are synergistic with CXCL10 agonists in inhibiting colon cancer growth [ Biomed Pharmacother, 2024, 179:117412] | PubMed: 39255734 |
| Granulocytic myeloid-derived suppressor cells increase infection risk via the IDO/IL-10 pathway in patients with hepatitis B virus-related liver failure [ Front Immunol, 2022, 13:966514] | PubMed: 36685516 |
| [ Oncoimmunology, 2017, ] | PubMed: 29209565 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。